
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is well-positioned for market success, with a strong financial position and upcoming Phase 2 studies planned for their various treatments, including a potential $50 oral NTCP inhibitor for hepatitis D virus in the works with Gilead. With a recent increase in revenue and a focus on potential monotherapy and combination treatments for PBC and PSC, the company has the potential to see significant growth and success in the near future. Additionally, their collaboration with Gilead for their HSV program and plans for other potential treatments showcase their commitment to innovation and expansion in the pharmaceutical industry.
Bears say
Assembly Biosciences is struggling to gain recognition for the commercial potential of their oral therapy for HSV and has faced delays and strategic pivots in their HBV program. While the company has a potential new partnership that could bring in non-dilutive funding, their current financials and lack of inclusion of their HBV program in their model suggest a potential lack of confidence in their success.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares